Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseSamantha Budd Haeberlein, Alfred Sandrock, Paul Aisen et al.|The Journal of Prevention of Alzheimer s Disease|2022Cited by 1.3k
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Bruce Cree, Karleyton C. Evans et al.|Neurology|2017Cited by 92